Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

An outbreak of coronavirus in Wuhan, China, has captured international attention, killing 82 in China (as of January 27 reports)...

View Blog Post
Blog Post

Heading into 2020, community-based pharmacies are focusing on patient-facing services and care as a way to achieve a variety of organizational and business goals. To that end, Drug Store News hosted as Industry Issues Summit in...

View Blog Post
Blog Post

Recent news from the Centers for Disease Control and Prevention (CDC) confirmed what circulating news reports were predicting: an early onset flu season. What remains to be...

View Blog Post

Filter by Type

Sign up to receive the latest news and information!

Sign Up